Literature DB >> 34070514

Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides.

Camille Roubille1,2, Soledad Henriquez3,4, Cédric Mercuzot1, Claire Duflos5, Bertrand Dunogue3,4, Karine Briot4,6, Loic Guillevin3,4, Benjamin Terrier3,4, Pierre Fesler1,2.   

Abstract

Despite improvement in the prognosis of ANCA-associated vasculitides (AAVs), increased mortality, mainly from a cardiovascular origin, persists. We aimed to determine the role of cardiovascular risk factors (CVRFs) on the occurrence of major cardiovascular events (MACEs) in AAVs. Patients with AAVs were successively included in a prospective cohort study, which assessed CVRFs (defined by age >50 years in men and >60 years in women, personal history of cardiovascular disease, smoking status, obesity, diabetes, dyslipidemia, hypertension, and sedentary lifestyle), the use of glucocorticoids and immunosuppressive agents at baseline and during follow-up, and the occurrence of MACEs. One hundred and three patients were included, with a median follow-up time of 3.5 years. In the glucocorticoids and cyclophosphamide adjusted multivariate analysis, the occurrence of MACEs was associated with older age (p = 0.001, OR = 14.71, 95% CI (confidence interval) = 2.98-72.68), cardiovascular history (p = 0.007, OR (odds ratio) = 6.54, 95% CI = 1.66-25.71), sedentary lifestyle (p = 0.011, OR = 4.50, 95% CI = 1.42-14.29), hypertension (p = 0.017, OR = 5.04, 95% CI = 1.33-19.12), and dyslipidemia (p = 0.03, OR = 3.86, 95% CI = 1.14-13.09). The occurrence of MACEs was associated with the number of CVRFs (p < 0.001), but not with the use of glucocorticoids or cyclophosphamide (p = 0.733 and p = 0.339, respectively). The implementation of a screening and management program for modifiable CVRFs, particularly hypertension, sedentary lifestyle, and dyslipidemia, may be beneficial for AAV patients in order to reduce their cardiovascular risk.

Entities:  

Keywords:  antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; cardiovascular risk; cardiovascular risk factors; dyslipidemia; hypertension; sedentary lifestyle

Year:  2021        PMID: 34070514     DOI: 10.3390/jcm10112299

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  48 in total

1.  Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).

Authors:  E W WALTON
Journal:  Br Med J       Date:  1958-08-02

2.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Authors:  R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

3.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

4.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

Authors:  J E Ware; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides.

Authors:  Karine Briot; Bertrand Dunogué; Soledad Henriquez; Adrien Etcheto; Sami Kolta; Alexis Régent; Pascal Cohen; Alice Berezne; Claire Le Jeunne; Luc Mouthon; Christian Roux; Loic Guillevin; Benjamin Terrier
Journal:  Clin Exp Rheumatol       Date:  2019-05-21       Impact factor: 4.473

6.  Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: results of a longterm followup study.

Authors:  Benjamin Terrier; Gilles Chironi; Christian Pagnoux; Pascal Cohen; Xavier Puéchal; Alain Simon; Luc Mouthon; Loïc Guillevin
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

7.  Wegener's granulomatosis: epidemiological and clinical features in a South Australian study.

Authors:  P Hissaria; F Z J Cai; M Ahern; M Smith; D Gillis; P Roberts-Thomson
Journal:  Intern Med J       Date:  2008-10       Impact factor: 2.048

8.  Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population-Based Study.

Authors:  J Antonio Aviña-Zubieta; Alice Mai; Neda Amiri; Natasha Dehghan; Ju Ann Tan; Eric C Sayre; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2016-09-29       Impact factor: 10.995

Review 9.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Authors:  Camille Roubille; Vincent Richer; Tara Starnino; Collette McCourt; Alexandra McFarlane; Patrick Fleming; Stephanie Siu; John Kraft; Charles Lynde; Janet Pope; Wayne Gulliver; Stephanie Keeling; Jan Dutz; Louis Bessette; Robert Bissonnette; Boulos Haraoui
Journal:  Ann Rheum Dis       Date:  2015-01-05       Impact factor: 19.103

10.  Endothelial dysfunction in patients with granulomatosis with polyangiitis: a case-control study.

Authors:  Renata Pacholczak; Stanisława Bazan-Socha; Teresa Iwaniec; Lech Zaręba; Stan Kielczewski; Jerzy A Walocha; Jacek Musiał; Jerzy Dropiński
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

View more
  3 in total

Review 1.  At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement.

Authors:  Milena Bond; Filippo Fagni; Michele Moretti; Federica Bello; Allyson Egan; Augusto Vaglio; Giacomo Emmi; Christian Dejaco
Journal:  Curr Rheumatol Rep       Date:  2022-10-04       Impact factor: 4.686

2.  Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

Authors:  Cyril Dumain; Jonathan Broner; Erik Arnaud; Emmanuel Dewavrin; Jan Holubar; Myriam Fantone; Benoit de Wazières; Simon Parreau; Pierre Fesler; Philippe Guilpain; Camille Roubille; Radjiv Goulabchand
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

3.  Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?

Authors:  Lauren Floyd; Adam D Morris; Alexander Woywodt; Ajay Dhaygude
Journal:  Clin Kidney J       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.